$39.99
Research Studies:
FREE Shipping on
orders over $200
ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY. The products offered on this website are intended solely for research and laboratory use. These products are not intended for human or animal consumption. They are not medicines or drugs and have not been evaluated or approved by the FDA to diagnose, treat, cure, or prevent any disease or medical condition. Any form of bodily introduction is strictly prohibited by law.
Melanotan II 10mg is a research-use-only laboratory material supplied for controlled research workflows, compound characterization, and analytical documentation review. It is manufactured under rigorous quality standards to support consistency, traceability, and batch-specific verification for qualified laboratory settings.
Melanotan II 10mg is intended strictly for laboratory research use only. This product is not intended for human or animal consumption, therapeutic use, diagnostic use, clinical use, veterinary use, or as a food, drug, cosmetic, dietary supplement, or household product.
| CAS No. | 121062-08-6 |
|---|---|
| Purity | ≥99% |
| Sequence | Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2 |
| Molecular Formula | C50H69N15O9 |
| Molecular Weight | 1024.18 g/mol |
| Synthesis | Solid-phase synthesis |
| Format | Lyophilized powder |
| Solubility | Soluble in water or 1% acetic acid |
| Stability & Storage | Stable for up to 24 months at -20°C. After reconstitution, may be stored at 4°C for up to 4 weeks or at -20°C for up to 6 months. |
| Applications | Skin pigmentation enhancement, libido and erectile function studies, appetite suppression research |
| Appearance | White lyophilized powder |
| Shipping Conditions | Shipped at ambient temperature; once received, store at -20°C |
| Regulatory/Compliance | Manufactured in a facility that adheres to cGMP guidelines |
| Safety Information | Refer to provided MSDS |
Consider these supplementary peptides for a comprehensive research approach.
For research teams deciding where to buy Melanotan II for research, the practical question is not personal application but whether the product-page documentation supports compound identity, analytical testing, and lot-level review. Melanotan II is cataloged in PubChem as a cyclic peptide with molecular formula C50H69N15O9 and molecular weight 1024.2 g/mol, and the IUPHAR/BPS Guide to Pharmacology lists MT-II as a peptide ligand with Melanotan II and MTII as synonyms [1] [2]. This guide frames Pure Lab Peptides product-page review around research-use-only documentation, melanocortin receptor literature, COA review, and supplier documentation boundaries.
Researchers looking to buy Melanotan II for research should first review RUO labeling, batch-specific COA availability, peptide identity records, HPLC purity data, LC-MS or mass spectrometry confirmation, lot traceability, and supplier documentation consistency. Products discussed in this article are intended for laboratory research use only and are not intended for human or animal consumption. Published melanocortin literature supports receptor-context review, not product claims [3] [4].
The phrase “buy Melanotan II for research” is commercial, but the safe product-page answer is technical. A research buyer is not evaluating personal outcomes; the research buyer is checking whether the compound name, COA, purity method, molecular identity, and lot details align with the product listing.
This reframing matters because melanocortin literature can be broad. The page should keep the focus on research procurement, documentation, and compound characterization instead of converting receptor literature into product-positioning claims.
A strong first-pass review should begin with the product label, batch-specific COA, identity method, purity method, lot number, test date, and supplier documentation. FDA analytical-method guidance describes analytical documentation as supporting identity, quality, purity, and related method-validation data in regulated contexts, which is useful as a general documentation model for research buyers reviewing laboratory materials [20].
Quality and documentation checklist:
RUO labeling sets the research boundary for the product page. FDA guidance for RUO and investigational labeling in the IVD context stresses that RUO labeling is tied to laboratory research positioning and should not be used to imply broader product status [17] [18].
For a peptide product page, that principle translates into a simple editorial rule: documentation can be discussed, but product claims, procedural guidance, and non-research positioning should stay out of the copy.
Melanotan II is a cyclic peptide listed in official and curated chemical databases under the synonym MT-II, with PubChem CID 92432 and IUPHAR/BPS GtoPdb Ligand ID 1323 [1] [2]. The FDA Global Substance Registration System also lists Melanotan II as a defined substance record with molecular formula C50H69N15O9 and molecular weight 1,024.18 [5].
The safest product-page classification is “Melanotan II research peptide.” IUPHAR/BPS classifies MT-II as a peptide ligand, while PubChem and FDA substance records support the compound’s molecular identity fields [1] [2] [5].
Researchers should treat this classification as a documentation anchor. The compound name, synonym set, molecular formula, and molecular weight should be consistent across the product page, COA, and any supplier documentation.
Published structure-activity literature describes Melanotan II as a cyclic analog of alpha-melanocyte-stimulating hormone, often abbreviated alpha-MSH or α-MSH [6]. Alpha-MSH belongs to the melanocortin peptide hormone family, and naturally occurring melanocortin ligands are discussed as POMC-derived signaling molecules in receptor literature [7].
For product-page architecture, that context helps define the same-lane research category. It does not support any product claim beyond compound and literature context.
Published MT-II literature often frames the compound through cyclic peptide structure, melanocortin receptor activity, and analog design [6] [13]. Structure-function studies have examined how MT-II side chains and cyclic structure relate to interaction with human melanocortin receptor models [13].
A product page should summarize that literature as background. It should not imply that a catalog item has the same setting, purpose, or evidentiary status as any study material.
The melanocortin receptor system includes five closely related G protein-coupled receptors: MC1R, MC2R, MC3R, MC4R, and MC5R [3] [4]. Melanotan II is generally discussed in the same research lane as alpha-MSH analogs and melanocortin receptor signaling literature [6] [7].
For Melanotan II product-page context, MC1R, MC3R, MC4R, and MC5R are the most relevant receptor labels to map. IUPHAR/BPS receptor-family data and published reviews separate these receptor subtypes by nomenclature, genes, transduction pathways, and endogenous ligand relationships [3] [8].
MC1R is commonly discussed in melanocyte biology literature, MC4R in central pathway research, and MC5R in broader receptor-function literature [10] [11] [12]. These are research categories, not product outcomes.
Receptor selectivity matters because compounds in this lane may interact with more than one melanocortin receptor subtype. MT-II structure-function literature has examined receptor activity at MC3R, MC4R, and MC5R models, while related cyclic lactam analog studies show how structural changes can alter receptor selectivity [13] [14].
For research buyers, this supports a documentation question: does the product page accurately identify the compound and avoid over-narrow receptor claims that the supplier documentation cannot support?
Melanocortin receptors are GPCRs, and signaling literature describes G-protein and downstream pathway mechanisms across the receptor family [3] [8]. Recent structural work has also examined ligand recognition and subtype selectivity in human melanocortin receptor models [16].
The key research boundary is simple. Pathway relevance can inform literature context, but it should not become language about product effects or product performance.
Pure Lab Peptides should position this page as a research-use-only documentation guide for qualified laboratory buyers. The page serves commercial research intent by helping technical procurement teams review COA availability, analytical data, identity documentation, and RUO labeling before selecting a research peptide.
A product-page research guide should answer procurement questions without becoming a wellness article, treatment guide, or instruction page. For Melanotan II, the safest structure is compound identity first, then receptor literature, then COA and analytical documentation.
That structure also supports search intent. Researchers who enter “buy Melanotan II for research” are best served by a product page that explains what to review, what to verify, and what claim boundaries apply.
Technical procurement intent is different from consumer shopping intent. Procurement teams need clear documentation signals: product name, synonym consistency, COA access, purity method, identity method, lot number, and label alignment.
FDA RUO guidance in the IVD setting reinforces the general concept that research labeling should remain separate from broader product representations [17]. Pure Lab Peptides copy should follow that same research-focused discipline.
A COA is one of the core documents for research-grade Melanotan review. It should identify the tested lot and summarize relevant analytical results in a way that can be matched to the product-page listing.
Certificates of analysis should identify the compound name, lot number, test date, analytical method, result fields, and source of testing. ISO/IEC 17025 describes laboratory competence and valid-result generation as central to testing and calibration laboratory confidence, which is useful context when evaluating outside analytical records [22].
For Melanotan II, the COA should also align with the synonym set and molecular identity fields shown in authoritative records such as PubChem, FDA GSRS, and IUPHAR/BPS [1] [2] [5].
COA consistency supports lot review by tying the product page, label, and analytical record to the same batch-specific material. Good documentation principles emphasize clear, traceable records, and research procurement teams can apply that same logic when matching a COA to a peptide vial [28].
A mismatch in compound name, lot number, or document date should prompt further documentation review before the material is selected for laboratory research.
Batch-specific documentation is stronger than generic documentation because it connects analytical results to a defined lot. This matters for peptide supplies because identity and purity records are only useful when the tested material and the listed material can be matched.
For procurement review, the practical question is whether the label, COA, catalog entry, and supplier documentation tell the same story.
Analytical testing is where product-page documentation becomes more concrete. HPLC, LC-MS, and mass spectrometry each support different parts of peptide characterization when documented correctly.
HPLC is widely used for peptide analysis and purification because it can separate peptide components and related impurities under defined chromatographic conditions [24]. A COA purity entry is more meaningful when the method is named, the chromatogram is available or summarized, and the lot identity is clear.
HPLC purity data should not be read as complete identity proof by itself. It is one analytical layer in a broader documentation review.
LC-MS combines chromatographic separation with mass-based detection, which can support peptide identity and impurity characterization when the method and data are suitable [25] [26]. Analytical reviews of peptide materials describe mass spectrometry as useful for structural and molecular characterization, especially when paired with orthogonal methods [27].
Lab-test verification workflow:
Mass spectrometry data add confidence when the expected molecular weight, mass-to-charge data, and method documentation align. NIST describes metrological traceability as a documented chain linking measurement results to references, which is a useful quality concept for analytical review [23].
For Melanotan II, mass data should be evaluated against the expected molecular identity documented in official records [1] [5].
A peptide vial label should be treated as a documentation checkpoint. It should not stand alone; it should match the product page, COA, and batch record fields.
A peptide vial label should clearly identify the compound name, lot number, catalog field, and RUO context. If a product listing identifies a lyophilized laboratory material, that description should remain a material-state descriptor rather than a procedural cue.
The label should also avoid unsupported claims. For research buyers, a clean label is one that helps document the material without shifting the page away from laboratory research.
Vial, lot, and catalog details must align because traceability depends on consistent identifiers. Documentation literature emphasizes that records create a detailed picture of what was done and what material is being represented [28].
When the product page, label, and COA use different identifiers, procurement teams cannot confidently connect analytical data to the listed research material.
A listing amount such as 10mg or peptide 10mg can identify catalog packaging, but it should not become a separate SEO target or instruction-oriented topic. The canonical entity remains Melanotan II.
This keeps the page focused on research-grade Melanotan documentation rather than variant-specific content.
Molecular documentation anchors the page in verifiable compound identity. For Melanotan II, the most relevant fields are compound name, synonym set, molecular formula, molecular weight, and database identifiers.
PubChem lists Melanotan II with molecular formula C50H69N15O9 and molecular weight 1024.2 g/mol, while FDA GSRS lists a molecular weight of 1,024.18 [1] [5]. Minor formatting differences can occur across databases, but the underlying identity fields should remain consistent.
When sequence data are shown in supplier documentation, researchers should compare that sequence against authoritative or literature-backed sources rather than treating a product-page label as the only identity record.
Synthetic peptide identity needs verification because a peptide can require both purity review and molecular identity confirmation. HPLC can support component separation, while LC-MS can add mass-based identity evidence [24] [25].
A strong product-page architecture should explain this distinction clearly: purity review asks how clean the material appears under a method; identity review asks whether the material matches the expected compound.
Reference-standard thinking helps teams evaluate whether analytical results are connected to a known comparator or documented expectation. ICH Q14 describes science- and risk-based approaches for developing analytical procedures, while ICH Q2(R2) describes validation principles for analytical procedures [21] [19].
For research procurement, this supports a simple practice: compare product documentation against stable identity records and batch-specific analytical files.
Melanotan II literature can support a receptor and pathway overview. It should not be used to create claims about what a research-use-only product does.
Published findings can support scientific background, receptor mapping, study-model context, and analytical-documentation standards. They cannot substitute for batch-specific COA data or convert a product listing into a claim.
| Research Area | What Literature Examines | Evidence Type | RUO Interpretation |
|---|---|---|---|
| Compound identity | Melanotan II molecular formula, molecular weight, synonyms, and identifiers [1] [2] [5] | Official database and curated ligand record | Supports identity cross-checking, not product claims |
| Receptor family | MC1R, MC2R, MC3R, MC4R, and MC5R nomenclature and signaling context [3] [4] [8] | Curated database and review literature | Supports melanocortin receptor research context |
| Analog structure | Cyclic alpha-MSH analog design and MT-II structure-function work [6] [13] [14] | Peer-reviewed structure-activity literature | Supports literature background and same-lane entity mapping |
| Analytical testing | HPLC and LC-MS roles in peptide characterization [24] [25] [26] | Analytical chemistry literature | Supports COA review and identity-documentation checks |
| Documentation quality | Laboratory competence, traceability, and record consistency [22] [23] [28] | Standards and documentation literature | Supports supplier documentation review |
Study context should limit product-page language by keeping findings tied to the model, method, and publication context. Some published literature outside the scope of RUO product use has examined this compound class in human study settings. That literature should not be interpreted as a use claim for research-use-only materials.
For Pure Lab Peptides, the safer editorial choice is to discuss receptor context, analytical verification, and claim boundaries instead of product outcomes.
Pathway relevance means the compound belongs in a research lane. It does not mean a catalog product is positioned for any non-research purpose.
Melanocortin receptor literature describes signal transduction, receptor subtype differences, and ligand-recognition features [8] [16]. Product-page language should convert that information into a research overview, not into claims.
Stock solution records can appear in laboratory documentation, but they should be handled carefully on a product page. The page may mention documentation fields, but it should not provide procedural steps.
Stock solution notes fit documentation review when they are treated as internal laboratory records. Useful fields may include compound name, lot number, responsible laboratory record, date, storage notation, and link to the COA.
This is a recordkeeping topic, not a product-page instruction. Documentation principles support clear, traceable records that can be reviewed later [28].
Pre-mixed language should be framed as a documentation and labeling issue. If a product or record uses that term, research teams should check what the label actually means, what analytical documentation supports the listing, and whether the term is consistent across supplier documents.
The page should avoid turning pre-mixed language into a practical instruction. The safe emphasis remains documentation review.
Supplier evaluation for buy Melanotan II for research decisions should prioritize documentation quality. The best product-page copy helps researchers compare evidence signals without implying personal or non-research purposes.
Research buyers should compare the product listing, COA, label, lot number, test date, analytical method, and storage documentation. ISO/IEC 17025 supports confidence in competent testing laboratories and valid results, while NIST traceability guidance supports the value of documented measurement relationships [22] [23].
A concise supplier documentation matrix should include:
Source quality filters reduce ambiguity by ranking evidence types. Official databases and peer-reviewed literature should guide compound identity and receptor context, while batch-specific supplier files should guide procurement review.
A safe filter looks like this: official database first, peer-reviewed receptor literature second, analytical method documentation third, supplier COA fourth, and marketing language last.
Grade language should be handled with care. Instead of relying on broad grade claims, research buyers should ask what documentation supports the listing.
For Melanotan II, stronger signals include certificates of analysis, HPLC data, LC-MS or mass spectrometry support, lot traceability, and consistent RUO labeling.
Common search terms can blur naming, category, and product-page boundaries. A strong product page clarifies those issues without adopting unsafe intent.
Melanotan II and Melanotan 2 are commonly treated as related naming variants in search behavior, while MT-II and MTII appear in curated ligand records [2]. A query such as buy Melanotan 2 for research should still resolve to the same documentation-first review process.
Consistent naming prevents duplicate targeting and keeps the canonical entity clear.
MT2 and MT-II should be interpreted as search and synonym variants, not separate product-page entities. The IUPHAR/BPS ligand page lists MT-II and MTII in relation to Melanotan II, which supports synonym awareness [2].
Misunderstandings to avoid:
The RUO boundary framework keeps the page focused on compound identity, literature context, documentation, and procurement review. It also prevents receptor-language drift into product claims.
Claim boundaries keep research pages focused by separating what literature examines from what the product page can say. FDA RUO guidance in its own domain shows why labeling and product representation must align with research positioning [17] [18].
For Melanotan II, that means the page may discuss melanocortin receptor research, but it should not position the product around non-research outcomes.
Literature context belongs in the background section. Product positioning belongs in documentation, COA review, identity testing, lot traceability, and RUO labeling.
This separation protects both clarity and compliance. It helps technical procurement teams understand the compound without turning published findings into claims about the material sold on the page.
Research pages should emphasize documentation quality. For a Melanotan II product page, the strongest topics are compound identity, COA review, HPLC purity data, LC-MS or mass spectrometry confirmation, lot-specific records, labeling consistency, and safe research-language boundaries.
Review the product-page documentation, COA details, and RUO labeling before evaluating this compound for laboratory research.
For research teams comparing peptide suppliers, prioritize COA availability, transparent labeling, analytical testing, and lot-level documentation. Explore Pure Lab Peptides for RUO peptide compounds with research-focused product information and available documentation.
Melanotan II is discussed as a synthetic research peptide in melanocortin receptor literature. Research pages should frame it by compound identity, synonym consistency, receptor-family context, and supporting documentation. The article identifies Melanotan II through database records and literature context, including MT-II synonym references and melanocortin receptor mapping [1] [2] [3].
Researchers should consider documentation before they buy Melanotan II for research. The key review points are RUO labeling, batch-specific COA availability, lot traceability, peptide identity records, purity testing, and supplier documentation consistency. A product page should help technical procurement teams evaluate records, not make product claims or shift into non-research positioning.
A melanocortin receptor agonist belongs in receptor-pathway research context. For Melanotan II, that framing should stay tied to melanocortin receptor mapping, ligand literature, and study-model interpretation. It should not become a product claim. Research teams can review how the compound is described across MC1R, MC3R, MC4R, and MC5R literature [3] [4].
Researchers should interpret Melanotan II cell signaling literature as pathway context. Melanocortin receptors are discussed as receptor systems with signal transduction pathways, but product-page copy should keep those findings separate from procurement language. The safer focus is receptor classification, compound characterization, COA review, and analytical testing rather than broad outcome statements [8].
In vitro research can add model-specific context for Melanotan II, but it does not replace product documentation. Research buyers should still review COA records, peptide identity confirmation, lot traceability, and supplier documentation. Published methods may inform how researchers read literature, while batch-level documents support evaluation of the specific research material.
Melanotan 1 should be mentioned only when it clarifies same-lane melanocortin research context. It should not create a separate product target or comparison built around non-research outcomes. For a Melanotan II page, the main entity remains Melanotan II, while related compounds may help explain naming, receptor literature, or source-quality review.
The following authors are recognized for published research that helped shape the scientific context discussed in this article.
Author profile: University of Arizona Profile
Dr. Victor J. Hruby’s published work is relevant to this article because it connects peptide chemistry, alpha-MSH analog design, and melanocortin receptor selectivity. His work cited in the article supports the research context for MT-II as a cyclic peptide in the melanocortin receptor lane, including structure-focused discussion of MC1R, MC3R, MC4R, and MC5R literature. His publications also help frame why compound characterization, receptor pathway research, and literature interpretation should remain distinct from RUO product positioning. That context is useful for laboratory research pages that need to explain pathway-focused background while keeping procurement discussion centered on documentation and published literature boundaries.
Selected publications:
Author profile: University of Arizona Cancer Center Profile
Dr. Minying Cai’s published work is relevant because it synthesizes melanocortin receptor literature and describes ligand-design strategies for receptor selectivity. The article’s research lane, Melanocortin Receptor Research, relies on this kind of pathway-focused literature to explain why Melanotan II should be framed through receptor classification, alpha-MSH analog context, and model-specific interpretation. Her publications provide background for biochemistry-oriented discussion of melanocortin receptor families while keeping the page focused on research documentation, supplier review, and published literature boundaries. This helps support a clear distinction between scientific context and research-use-only product-page positioning.
Selected publications:
This research disclaimer clarifies how this page handles published literature and search language around Melanotan II. In Melanocortin Receptor Research content, terms such as tan, pigmentation, skin pigmentation, melanin, sun exposure, tanning peptide, and pharmaceutical grade peptides can drift into consumer-facing, wellness, appearance-focused, or product-claim language when framed incorrectly. Related phrases such as penile erection, erectile dysfunction, food intake, body weight, and appetite suppression also require careful separation from product positioning.
Here, those phrases are handled only as research-language examples and boundary-sensitive terminology, not as product purposes, outcomes, instructions, or recommendations. The focus remains on Melanotan II identity, COA review, analytical testing, peptide purity, lot traceability, research-use-only labeling, product documentation, and published literature boundaries. Any discussion of preclinical literature, receptor-pathway context, or source language should stay tied to model-specific research interpretation and documentation review.
Our team is ready to assist you with any inquiries regarding our catalogue of peptides and their applications.
Discount Applied Successfully!
Your savings have been added to the cart.
There are no reviews yet.